Andreas has been a memmber of the Bayer HealthCare Executive COmmittee as Head of Pharmaceuticals Reserch since February 2007. He has also been in charge of Research in the Animal Health Division since March 2011. Andreas has worked at various research institutes in Ge…more ›

Dr. Anand Tharmaratnam is Senior Vice President and Head of Asia Markets, Clinical Development for Quintiles. In this role, Dr. Tharmaratnam has responsibility for the Quintiles clinical development business across the Asia-Pacific region, including Japan. In the Asia-P…more ›

Chihiro has more than 30 years of pharmaceutical industry experience and is a highly regarded individual of the industry. He has led the company’s global business expansion and managed several deals including the acquisition of OSI Pharmaceuticals and alliances with Amb…more ›

Dr. Sam Azoulay is the Senior Vice President, Medical & Development, of the Emerging Markets and Established Products Business Units for Pfizer Inc. Dr. Azoulay joined Pfizer as a result of the company’s acquisition of Parke Davis, Warner Lambert in 2000, where h…more ›

Anders is responsible for R&D operating across drug development and life cycle management delivering submissions and approvals in Astrazeneca. He was also in charge of strategy, portfolio and alliances in the company. He will be discussing in our keynote panel on th…more ›

Helmut Haning studied chemistry at the University of Mainz, Germany and the Polymer Science and Engineering Department, Massachusetts, USA. After receiving his MS in the field of stereoselective synthesis, he did his PhD in the Goup of Prof. M. T. Reetz at the Max Planc…more ›

Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit at Novartis, GNF/NIBR. Yuan joined Novartis in 2008. Previously, Yuan has held the following positions: 2008-2011: Novartis, Global Head and Vice President of Process Sciences & …more ›

In his role as Vice President, BioProcess R&D NA at sanofi pasteur, Dr. D?Amore provides leadership to a Division of over 100 people and contributes to the growth and profitability of the Company through the overall direction, administration and management of all ac…more ›

Jeffrey S. Kasher, Ph.D., was named vice president and chief operating officer, global clinical development for Eli Lilly and Company in February 2007. He received a bachelor of science degree in chemistry from Franklin & Marshall College (Lancaster, Pa), a doctor…more ›

Professor Ceri Davies graduated from the University of Bristol with a first class honours degree and PhD in pharmacology and ran an independent academic laboratory at the University of Edinburgh before leaving academia in 1998 to join the pharmaceutical industry at Orga…more ›

Dr. Werner Katzmann holds an MD and a PhD from the University of Tübingen, Germany. In April 2011, Werner joined Biogen Idec as the Senior Director of Regional Medical Affairs for Asia Pacific. In this position, he is building up a medical and scientific infrastruc…more ›

Hong Bo has been instrumental in several life science start-up operations in Asia. In this conference, she will bring you through the steps how emerging companies from Asian Biotech hubs can effectively tap into available funding opportunities.

Carrie has led the Life Sciences practice in CM Capital Investments for over 10 years, investing and been the inventor of a number of patents and has been involved in the complete product lifecycle, including medical research in London and developing, licensing and mar…more ›

John has a vast amount of experience in investing in lifesciene companies and is also special advisor to the Singapore Economic Development Board. He also serves as Board Chairman of Ambrx and Envoy Therapeutics as well as on the Boards of Directors of Igenica, Ingenuit…more ›

Alfred Scheidegger is the founder and CEO of Nextech Venture, Ltd., a globally active investment management firm based in Zurich, Switzerland. Nextech Venture manages and advises three investment funds of USD 166 million with a focus on oncology. Prior to founding Nexte…more ›

E. Stewart Geary, M.D, has worked at Eisai since 1996 in pharmacovigilance, clinical safety and regulatory science. He is currently a member of the CIOMS IX Working Group on Medicinal Product Risk Management, the Executive Committees of the Japanese Association of Pharm…more ›

Mr. Sampad Bhattacharya , Vice President Operation , Sun Pharmaceutical Industries Limited, India. is heading manufacturing operations of multi locational formulation plants of Sun Pharma in India. He has been in the industry for 32 years and have headed ,Quality…more ›

Dr. Shivraj Dasari is Vice President – Quality Management & Regulatory Affairs, at InnoBio Ventures Sdn.Bhd, Malaysia. He is currently responsible for developing and implementing Quality Management systems meeting USFDA, EMEA, and Malaysian FDA (NPCB) standards. He …more ›

Ken Araki has a responsibility to initiate and manage global corporate-wide strategic projects to support Takeda’s Senior Management team including President & CEO at the company. His team is also heavily involved in building up company’s strategic direction based o…more ›

Kiran Mazumdar-Shaw's pioneering efforts in biotechnology have drawn global recognition both for Indian Industry and Biocon. Her unique vision has steered Biocon's transition from an industrial enzymes company to an integrated biopharmaceutical company with stra…more ›

Dr. Mu joined Hutchison MediPharma in 2010 as the Senior Vice President, Clinical Research & Development. He has over 16 years of clinical research and development experience focusing on oncology, having held medical and clinical leadership positions at several lea…more ›

Dr. Chang is currently the Medical Director at Abbott Laboratories responsible for the territories of Taiwan and South Korea where she leads the Affiliate Medical Department Team and the Medical Department. In her current role, Dr. Chang sets the vision and direction fo…more ›